Jilin Jian Yisheng Pharmaceutical Co., Ltd. (SHE:002566)
China · Delayed Price · Currency is CNY 8.32
-0.01 (-0.12%)
At close: Feb 13, 2026
SHE:002566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 636.02 | 665.38 | 850.63 | 829.06 | 875.14 | 841.51 |
Other Revenue | 3.09 | 3.09 | 3.03 | 0.98 | 2.79 | 1.08 |
| 639.1 | 668.47 | 853.66 | 830.04 | 877.93 | 842.59 | |
Revenue Growth (YoY) | -9.74% | -21.69% | 2.85% | -5.46% | 4.19% | -16.80% |
Cost of Revenue | 165.21 | 174.13 | 224.8 | 215.44 | 221.22 | 217.11 |
Gross Profit | 473.89 | 494.34 | 628.87 | 614.6 | 656.71 | 625.48 |
Selling, General & Admin | 408.68 | 428.17 | 509.94 | 489.33 | 506.34 | 492.27 |
Research & Development | 13.4 | 16.22 | 18.68 | 18.78 | 20.89 | 15.71 |
Other Operating Expenses | 29.93 | 14 | -6.62 | 16.5 | 15.96 | 13.96 |
Operating Expenses | 453.69 | 458.4 | 522 | 525.88 | 542.74 | 528.08 |
Operating Income | 20.2 | 35.95 | 106.86 | 88.73 | 113.97 | 97.4 |
Interest Expense | -13.31 | -13.84 | -13.66 | -14.03 | -13.36 | -13.1 |
Interest & Investment Income | 12.66 | 11.69 | 16.31 | 11.14 | 9.27 | 3.28 |
Currency Exchange Gain (Loss) | -0.14 | -0.14 | -0.12 | -0 | - | 0.02 |
Other Non Operating Income (Expenses) | 2.11 | 0.23 | -0.57 | -1.92 | 0.13 | -0.55 |
EBT Excluding Unusual Items | 21.52 | 33.89 | 108.83 | 83.91 | 110.01 | 87.06 |
Gain (Loss) on Sale of Investments | 0.52 | 6.41 | 2.39 | -0.32 | 0.16 | - |
Gain (Loss) on Sale of Assets | 0.16 | 0.29 | 0.78 | - | - | - |
Asset Writedown | -0.27 | -0.27 | -0.24 | -0.27 | -0.28 | 0.02 |
Other Unusual Items | 27.05 | 19.22 | 0 | 17.9 | 13.48 | 17.96 |
Pretax Income | 48.99 | 59.55 | 111.76 | 101.23 | 123.37 | 105.04 |
Income Tax Expense | 7.31 | 8.89 | 15.65 | 12.91 | 18.67 | 15.42 |
Earnings From Continuing Operations | 41.67 | 50.66 | 96.11 | 88.32 | 104.7 | 89.62 |
Minority Interest in Earnings | -1.32 | 1.43 | -1.38 | -5.22 | -8.68 | -9.55 |
Net Income | 40.35 | 52.09 | 94.73 | 83.1 | 96.02 | 80.06 |
Net Income to Common | 40.35 | 52.09 | 94.73 | 83.1 | 96.02 | 80.06 |
Net Income Growth | -44.06% | -45.02% | 14.00% | -13.46% | 19.93% | 4.52% |
Shares Outstanding (Basic) | 331 | 331 | 331 | 331 | 331 | 331 |
Shares Outstanding (Diluted) | 331 | 331 | 331 | 331 | 331 | 331 |
Shares Change (YoY) | 0.01% | -0.03% | 0.02% | -0.02% | 0.01% | -0.02% |
EPS (Basic) | 0.12 | 0.16 | 0.29 | 0.25 | 0.29 | 0.24 |
EPS (Diluted) | 0.12 | 0.16 | 0.29 | 0.25 | 0.29 | 0.24 |
EPS Growth | -44.06% | -45.00% | 13.98% | -13.44% | 19.93% | 4.54% |
Free Cash Flow | 46.15 | 43 | 173.36 | 104.49 | 108.04 | 127.58 |
Free Cash Flow Per Share | 0.14 | 0.13 | 0.52 | 0.32 | 0.33 | 0.39 |
Dividend Per Share | 0.100 | 0.100 | 0.150 | 0.050 | 0.030 | 0.030 |
Dividend Growth | -33.33% | -33.33% | 200.00% | 66.67% | - | -40.00% |
Gross Margin | 74.15% | 73.95% | 73.67% | 74.05% | 74.80% | 74.23% |
Operating Margin | 3.16% | 5.38% | 12.52% | 10.69% | 12.98% | 11.56% |
Profit Margin | 6.31% | 7.79% | 11.10% | 10.01% | 10.94% | 9.50% |
Free Cash Flow Margin | 7.22% | 6.43% | 20.31% | 12.59% | 12.31% | 15.14% |
EBITDA | 60.86 | 78.56 | 152.08 | 128.82 | 154.25 | 138.06 |
EBITDA Margin | 9.52% | 11.75% | 17.82% | 15.52% | 17.57% | 16.39% |
D&A For EBITDA | 40.66 | 42.61 | 45.21 | 40.09 | 40.28 | 40.67 |
EBIT | 20.2 | 35.95 | 106.86 | 88.73 | 113.97 | 97.4 |
EBIT Margin | 3.16% | 5.38% | 12.52% | 10.69% | 12.98% | 11.56% |
Effective Tax Rate | 14.93% | 14.93% | 14.00% | 12.75% | 15.14% | 14.68% |
Revenue as Reported | 639.1 | 668.47 | 853.66 | 830.04 | 877.93 | 842.59 |
Advertising Expenses | - | 6.21 | 6.7 | 4.4 | 7.97 | 8.53 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.